Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen's Harper Says Repatha Is Priced Right

Executive Summary

The things that keep Sean Harper up at night have changed over the last few years as science has advanced and the drug development landscape has changed. Harper, who is the head of R&D at big biotech Amgen Inc., once worried that his company wouldn't be able to keep up, now he's concerned with where the money is going to come from.

You may also be interested in...

Regeneron: PCSK9s Drowning In Paperwork

A common problem is plaguing both Regeneron Pharmaceuticals Inc. and Amgen Inc. – paperwork, specifically, the abundance of paperwork patients and physicians need to fill out to prescribe a PCSK9 inhibitor.

PCSK9s: Discount Prompts NICE Turnaround on Sanofi's Praluent

HTA body NICE has Okayed PCSK9 inhibitors Repatha and Praluent for adults with primary hypercholesterolaemia or mixed dyslipidaemia for use on the National Health Service IN England and Wales. However, restrictions on prescribing will likely limit sales.

More Troubles For Martin Shkreli – That Guy Drug Makers Despise

Martin Shkreli, who is largely despised by the biopharmaceutical industry, may be in even deeper trouble than he thought, with prosecutors telling a judge on May 3 they are considering additional charges against the former drug company CEO, who already is facing seven criminal counts, including securities fraud. Turing Pharmaceuticals Inc., one of the firms Shkreli created and used to lead, also is up against a new lawsuit from Impax Laboratories Inc., which is claiming breach of contract involving the drug Daraprim, whose price was hiked by more than 5,000%.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts